Search results
Results from the WOW.Com Content Network
Amgen presented results from the Phase 3 ADVANCE trial of Otezla in patients with plaque psoriasis at the American Academy of Dermatology Virtual Meeting Experience 2021. In the placebo-controlled ...
Amgen (AMGN) concludes the pending buyout of Celgene's psoriasis drug Otezla to acquire its worldwide rights. The company also hikes its overall 2019 view. Stock gains.
Otezla, which Amgen acquired last year from Celgene Corp as part of Celgene's buyout by Bristol Myers Squibb Co <BMY.N>, helps reduce overactive inflammation. Amgen studying Otezla for coronavirus ...
AMGen corporate logo, 1983 Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics. [6] [7] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin. [8]
Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. [4] The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). [ 4 ]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Amgen is one of those companies developing brand-new obesity therapies. ... with projected 2030 sales of $2.1 billion and a net present value of $12.4 ... and immunosuppressant Otezla are ...
For premium support please call: 800-290-4726 more ways to reach us